Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.

Hodgkin LymphomaB-Cell LymphomaRelapsed B-cell NHL

M.D. Anderson Cancer CenterNCT05615636